Mounjaro Safety in Older Adults: What the Label and Studies Show
A source-bounded guide to Mounjaro in adults 65 and older: trial representation, dosing, kidney function, GI effects, hypoglycemia, frailty, and evidence gaps.
GLP-1 Medicine
Evidence-based guidance on semaglutide, tirzepatide, GLP-1 access, insurance coverage, side effects, dosing, weight-loss outcomes, diabetes care, and real-world safety.
3,543reviewed articles
242topic clusters
Sep 5, 2026latest review
GLP-1 medications are drugs that act like glucagon-like peptide-1, a hormone the gut releases after eating. The most common are semaglutide and tirzepatide. Tirzepatide also acts on a second hormone, GIP, which is why it is sometimes called a dual agonist.
Familiar brand names include Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide). Liraglutide and oral semaglutide are also part of this class.
How do GLP-1 medications work?
GLP-1 medications slow how quickly the stomach empties, increase the feeling of fullness, and prompt the pancreas to release insulin when blood sugar is high. The result is reduced appetite, steadier blood sugar, and gradual weight loss.
What are GLP-1 medications used for?
GLP-1 medications are FDA approved for type 2 diabetes and for chronic weight management, and some have additional approved uses. The specific approval depends on the drug.
- Type 2 diabetes (for example, Ozempic, Mounjaro).
- Chronic weight management in eligible adults (Wegovy, Zepbound).
- Reducing cardiovascular risk in some patients (semaglutide).
- These approvals are drug-specific, so the right option depends on the goal and medical history.
What are the side effects of GLP-1 medications?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually strongest when starting or increasing the dose. Less common but serious risks include gallbladder problems and pancreatitis, and these drugs carry a warning about thyroid tumors based on animal studies.
Semaglutide vs tirzepatide: what is the difference?
Both are weekly injectable GLP-1 medications, but tirzepatide also activates the GIP receptor. In head-to-head and trial data, tirzepatide has generally produced greater average weight loss, though the best choice depends on tolerability, cost, and medical history.
Explore the molecule guides
Frequently asked questions
What are GLP-1 medications?
They are drugs that mimic the gut hormone GLP-1 to lower blood sugar and reduce appetite. Semaglutide and tirzepatide are the most common.
How do GLP-1 medications cause weight loss?
They slow stomach emptying and increase fullness, which reduces appetite and calorie intake, leading to gradual weight loss.
What is the difference between semaglutide and tirzepatide?
Both are weekly GLP-1 injections, but tirzepatide also acts on the GIP receptor and has generally produced greater average weight loss in trials.
What are the main side effects of GLP-1 medications?
Most commonly nausea, vomiting, diarrhea, and constipation, especially when starting. Rare but serious risks include gallbladder problems and pancreatitis.
High-intent clinical paths
Restarting Zepbound After a Gap: Label Rules and the Evidence Gap
What the current Zepbound label says about one missed dose, what it does not say about longer interruptions, and how trial restart rules differ from prescribing instructions.
Wegovy Geriatric Safety: What Adults 65 and Older Need to Know About Semaglutide 2.4 mg
An evidence map for Wegovy in adults 65 and older, separating FDA label findings from extrapolation about muscle, dehydration, fractures, and monitoring.
Browse by clinical intent
Core GLP-1 Drugs
Semaglutide, tirzepatide, oral GLP-1s, branded options, compounded-equivalent explainers, and clinical comparisons.
- Mounjaro Safety in Older Adults: What the Label and Studies Show
- Restarting Zepbound After a Gap: Label Rules and the Evidence Gap
- Wegovy Geriatric Safety: What Adults 65 and Older Need to Know About Semaglutide 2.4 mg
- Wegovy Missed Dose: The Current FDA Instructions for Weekly Injections
- Zepbound for Teens: No FDA Pediatric Dose Yet
Access and Coverage
Insurance, state access, Medicare, Medicaid, copay programs, out-of-pocket cost, and pharmacy logistics.
- Retatrutide Methods: Market-status Boundaries — Active-control Design
- Retatrutide Methods: Market-status Boundaries — Indication Alignment
- Retatrutide Methods: Market-status Boundaries — Follow-up Duration
- Retatrutide Methods: Market-status Boundaries — Regulatory-label Context
- Wegovy Patient Assistance for Low-Income: Every Program, Step by Step
Side Effects and Safety
GI effects, gallbladder risk, pancreatitis signals, discontinuation, switching, monitoring, and when to call a clinician.
- Retatrutide Methods: Adverse-event Ascertainment — Active-control Design
- Retatrutide Methods: Adverse-event Ascertainment — Indication Alignment
- Retatrutide Methods: Adverse-event Ascertainment — Follow-up Duration
- Retatrutide Methods: Adverse-event Ascertainment — Regulatory-label Context
- Zepbound Side Effects: Potentially Permanent Adverse Events Explained
GLP-1 Medicine explorer
Showing 300 of 3,543 clinical reviews.
Mounjaro Safety in Older Adults: What the Label and Studies Show
A source-bounded guide to Mounjaro in adults 65 and older: trial representation, dosing, kidney function, GI effects, hypoglycemia, frailty, and evidence gaps.
Restarting Zepbound After a Gap: Label Rules and the Evidence Gap
What the current Zepbound label says about one missed dose, what it does not say about longer interruptions, and how trial restart rules differ from prescribing instructions.
Wegovy Geriatric Safety: What Adults 65 and Older Need to Know About Semaglutide 2.4 mg
An evidence map for Wegovy in adults 65 and older, separating FDA label findings from extrapolation about muscle, dehydration, fractures, and monitoring.
Wegovy Missed Dose: The Current FDA Instructions for Weekly Injections
Use the current FDA label's 48-hour decision point for one missed Wegovy injection, and learn what the label does-and does not-say after two or more missed doses.
Zepbound for Teens: No FDA Pediatric Dose Yet
Zepbound has no FDA-approved dose for patients under 18. See what the current label, adolescent trial, and pediatric tirzepatide evidence do-and do not-support.
Stopping Zepbound: No FDA Taper, What Withdrawal Trials Show
Zepbound has no FDA taper schedule. Compare continuation, 5 mg maintenance, and withdrawal evidence, then build a reason-specific stop and follow-up plan.
Zepbound for Older Adults: What the FDA Data Can and Cannot Show
Zepbound has no age-based dose adjustment, but the evidence after age 75 is limited. See the FDA denominators, body-composition limits, and practical risk review.
Zepbound Overdose or Double Dose: What to Do Now
If you took too much Zepbound or dosed twice, contact Poison Help now. Learn what details to gather, what symptoms matter, and why observation may last several days.
Retatrutide Methods: Indirect-evidence Limits — Cross-study Context
Primary-source review of indirect-evidence limits and cross-study context: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Market-status Boundaries — Active-control Design
Primary-source review of market-status boundaries and active-control design: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Endpoint Interpretation — Active-control Design
Primary-source review of endpoint interpretation and active-control design: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Adverse-event Ascertainment — Active-control Design
Primary-source review of adverse-event ascertainment and active-control design: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Treatment-sequence Evidence — Active-control Design
Primary-source review of treatment-sequence evidence and active-control design: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Market-status Boundaries — Indication Alignment
Primary-source review of market-status boundaries and indication alignment: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Endpoint Interpretation — Indication Alignment
Primary-source review of endpoint interpretation and indication alignment: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Adverse-event Ascertainment — Indication Alignment
Primary-source review of adverse-event ascertainment and indication alignment: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Treatment-sequence Evidence — Indication Alignment
Primary-source review of treatment-sequence evidence and indication alignment: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Market-status Boundaries — Follow-up Duration
Primary-source review of market-status boundaries and follow-up duration: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Endpoint Interpretation — Follow-up Duration
Primary-source review of endpoint interpretation and follow-up duration: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Adverse-event Ascertainment — Follow-up Duration
Primary-source review of adverse-event ascertainment and follow-up duration: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Treatment-sequence Evidence — Follow-up Duration
Primary-source review of treatment-sequence evidence and follow-up duration: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Market-status Boundaries — Regulatory-label Context
Primary-source review of market-status boundaries and regulatory-label context: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Endpoint Interpretation — Regulatory-label Context
Primary-source review of endpoint interpretation and regulatory-label context: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Adverse-event Ascertainment — Regulatory-label Context
Primary-source review of adverse-event ascertainment and regulatory-label context: study design, evidence limits, registry records, and current FDA…
Retatrutide Methods: Treatment-sequence Evidence — Regulatory-label Context
Primary-source review of treatment-sequence evidence and regulatory-label context: study design, evidence limits, registry records, and current FDA…
Retatrutide Methods: Concurrent-use Evidence — Active-control Design
Primary-source review of concurrent-use evidence and active-control design: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Follow-up Windows — Active-control Design
Primary-source review of follow-up windows and active-control design: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: External Validity — Active-control Design
Primary-source review of external validity and active-control design: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Subgroup Representation — Active-control Design
Primary-source review of subgroup representation and active-control design: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Protocol Escalation — Active-control Design
Primary-source review of protocol escalation and active-control design: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Prior-therapy Evidence — Active-control Design
Primary-source review of prior-therapy evidence and active-control design: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Concurrent-use Evidence — Indication Alignment
Primary-source review of concurrent-use evidence and indication alignment: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Follow-up Windows — Indication Alignment
Primary-source review of follow-up windows and indication alignment: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: External Validity — Indication Alignment
Primary-source review of external validity and indication alignment: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Subgroup Representation — Indication Alignment
Primary-source review of subgroup representation and indication alignment: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Protocol Escalation — Indication Alignment
Primary-source review of protocol escalation and indication alignment: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Prior-therapy Evidence — Indication Alignment
Primary-source review of prior-therapy evidence and indication alignment: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Concurrent-use Evidence — Follow-up Duration
Primary-source review of concurrent-use evidence and follow-up duration: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Follow-up Windows — Follow-up Duration
Primary-source review of follow-up windows and follow-up duration: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: External Validity — Follow-up Duration
Primary-source review of external validity and follow-up duration: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Subgroup Representation — Follow-up Duration
Primary-source review of subgroup representation and follow-up duration: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Prior-therapy Evidence — Follow-up Duration
Primary-source review of prior-therapy evidence and follow-up duration: study design, evidence limits, registry records, and current FDA status. Updated…
Retatrutide Methods: Concurrent-use Evidence — Regulatory-label Context
Primary-source review of concurrent-use evidence and regulatory-label context: study design, evidence limits, registry records, and current FDA status…
Retatrutide Methods: Prior-therapy Evidence — Regulatory-label Context
Primary-source review of prior-therapy evidence and regulatory-label context: study design, evidence limits, registry records, and current FDA status…
Zepbound (Tirzepatide) in Adolescents Ages 12 to 17: What We Know About Off-Label Use
Tirzepatide is not FDA-approved for adolescent obesity. This evidence-based guide explains the current label, approved alternatives, and the limits of the available evidence.
Mounjaro for Heart Failure: Off-Label Dosing Protocol, Evidence, and Clinical Guidance
Mounjaro has no FDA-approved heart-failure dose. Review the final SUMMIT trial in obesity-related HFpEF, what its results show, and why trial titration is not a personal dosing protocol.
Wegovy for Binge Eating Disorder: What the Evidence Actually Shows
What research does and does not show about semaglutide for binge-eating disorder, how this differs from obesity treatment, and why diagnosis-specific care matters.
Zepbound Side Effects: Potentially Permanent Adverse Events Explained
A source-checked guide to Zepbound side effects, separating common reversible symptoms from rare complications that can have lasting consequences and risks that remain uncertain.
Wegovy Sulfur Burps: Alternatives Without This Side Effect
What is known about burping and upper-GI symptoms with Wegovy, which warning signs matter, and what evidence can and cannot predict about alternative treatments.
Can I Take Magnesium With Mounjaro (Tirzepatide)?
What is known about magnesium supplements, tirzepatide, gastrointestinal symptoms, and when to ask a clinician or pharmacist.
Rybelsus Efficacy Plateau: How to Titrate Oral Semaglutide and Restore Results
How to discuss an oral-semaglutide plateau safely, use current product instructions, and avoid self-directed dose changes.
SUSTAIN-6 Follow-Up: What Later Semaglutide Studies Confirmed
SUSTAIN-6 had no randomized long-term extension. See what its post hoc analyses, SELECT, and FLOW add about cardiovascular, kidney, and retinopathy outcomes.
Mounjaro Safety in Adults 50 to 64: What Older Patients Need to Know
An evidence-based guide to tirzepatide (Mounjaro) safety for adults aged 50 to 64, covering cardiovascular risk, polypharmacy, hormonal transition, dosing, and individualized monitoring.
Can I Take Ginseng With Zepbound? Interaction Risk, Monitoring, and Clinical Guidance
Can you use ginseng with Zepbound? Review the limited evidence, glucose and warfarin concerns, product-quality issues, and why no spacing schedule is proven.
Rybelsus (Oral Semaglutide) in Children Under 12: What the Off-Label Evidence Actually Shows
An evidence-based review of oral semaglutide (Rybelsus) in children under 12, including FDA status, the completed pediatric trial, current evidence gaps, and approved alternatives.
How GLP-1s Like Semaglutide Help With Impulse Control
Semaglutide can reduce hunger, food cravings, and loss-of-control eating. Evidence for alcohol, nicotine, and broader impulse control is promising but still indication-specific and incomplete.
Wegovy Patient Assistance for Low-Income: Every Program, Step by Step
A current 2026 guide to Wegovy savings offers, self-pay prices, the Medicare GLP-1 Bridge, insurance appeals, and low-income access checks.
Ozempic Side Effects: What the Trials Actually Show, From Common Nausea to Rare Risks
A guide to Ozempic (semaglutide) side effects: how common nausea and GI effects really are in trials, the serious risks like pancreatitis and gastroparesis, the NAION eye question, and when to call your prescriber.
Ozempic: Uses, Dosing, and How It Compares to Wegovy
Ozempic is semaglutide approved for type 2 diabetes and cardiovascular risk, not weight loss. See dosing, HbA1c results, and how it differs from Wegovy.
Rybelsus (Oral Semaglutide): Uses, Dosing, and Results
Rybelsus is a once-daily oral semaglutide pill approved for type 2 diabetes, lowering HbA1c 1.0-1.4% and causing modest weight loss versus injectable GLP-1s.
Showing the first 60 matches. Use search or filters to narrow the library.